The work
The proof is on the page.
Reports and congress intelligence, newest first. Every claim traced to its source; an adversarial model has tried to break each one. Selected calls are pre-registered in public before the data lands.
- Jun 15, 2026From pilot to protagonistPharma is handing AI the decisions, not just the slides — the premium now moves to whoever can still prove the machine is right.
- Jun 10, 2026EHA 2026 Signal RadarThe hematology readouts that move the tape, mapped against the published record before the print.
- Jun 4, 2026ASCO 2026 — RAS-pathway clusterWhere the RAS and selective-kinase oncology programs stand, read from primary literature rather than company decks.
- Jun 4, 2026ASCO 2026 — congress intelligenceThe dated diligence read on the oncology catalysts that matter, before the data lands.
- May 20, 2026Rezolute (RZLT)A hypoglycemia program judged on its trial design and its filings, not its narrative.
- May 5, 2026Immunome (IMNM)Phase 3 hazard ratio 0.16, NDA filed — a clean desmoid-tumor win, read against the published record.
- Apr 25, 2026Abivax (ABVX)Two Phase 3 inductions hit; a $9.3B valuation now rests on a single maintenance readout.
- Apr 25, 2026Neurogene (NGNE)A pediatric HLH death the deck omits — the kind of fact a primary-source audit surfaces.